Sigma-Aldrich and Oxford BioMedica Pursue Protection of RNAi-Related Intellectual Property; File Suit Against Open Biosystems
The suit states that, among other products, Open Biosystems' Lentiviral shRNAmir Library is marketed and sold to researchers and research institutions for incorporation into viral particles that infringe one or more claims of the patents.
Sigma-Aldrich has invested in its RNAi program through significant intellectual property and licensing activities. The lawsuit filed against Open Biosystems is a result of Sigma-Aldrich's desire to actively protect its intellectual property in this field.
Other news from the department politics & laws
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.